Efficacy analysis of SEAM preconditioning regimen followed by autologous hematopoietic stem cell transplantation in relapsed/refractory non-Hodgkin lymphoma
10.3760/cma.j.cn115356-20210105-00008
- VernacularTitle:SEAM预处理方案用于复发难治非霍奇金淋巴瘤自体造血干细胞移植的效果分析
- Author:
Jing FENG
1
;
Sanbin WANG
Author Information
1. 昆明医科大学研究生院，昆明 650500
- Keywords:
Lymphoma, non-Hodgkin;
Hematopoietic stem cell transplantation;
Transplantation conditioning
- From:
Journal of Leukemia & Lymphoma
2021;30(7):395-399
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the efficacy and adverse effects of SEAM (semustine, etoposide, cytarabine and melphalan) preconditioning regimen followed by autologous hematopoietic stem cell transplantation (auto-HSCT) in treatment of patients with relapsed/refractory non-Hodgkin's lymphoma (NHL).Methods:The clinical data of 20 NHL patients receiveing conditioning regimen followed by auto-HSCT in 920th Hospital of PLA Joint Logistic Support Force from January 2015 to September 2020 were retrospectively analyzed. The pretreatment-related adverse effects, recovery of hematopoietic function after transplantation, and disease prognosis were observed.Results:During the pretreatment of 20 patients, 1 patient had pulmonary infection, 8 patients had nausea and vomiting, 3 patients had diarrhea, 1 patient had fever, 1 patient had lung injury, and 1 patient had mucositis. After auto-HSCT, 16 patients achieved hematopoietic reconstruction, the median time of neutrophil engraftment (neutrophil ≥0.5×10 9/L) was 13 d (8-30 d) and the median time of platelet engraftment (platelets ≥20×10 9/L) was 13 d (9-37 d). The median follow-up time was 27 months (3-65 months). Until the end of the follow-up, 16 (80%) patients had disease-free survival, 4 patients died, and no patient had recurrence and disease progression; non-relapse mortality was 20%. Conclusions:SEAM conditioning regimen followed by auto-HSCT has a better tolerance, less adverse events, quick recovery of hematopoietic reconstruction and good efficacy for NHL patients.
